PURPOSE: To evaluate the feasibility of developing a novel mini drug pump for ophthalmic use. METHODS: Using principles of microelectromechanical systems engineering, a mini drug pump was fabricated. The pumping mechanism is based on electrolysis, and the pump includes a drug refill port as well as a check valve to control drug delivery. Drug pumps were tested first on the benchtop and then after implantation in rabbits. For the latter, we implanted 4 elliptical (9.9 x 7.7 x 1.8 mm) non-electrically active pumps into 4 rabbits. The procedure is similar to implantation of a glaucoma seton. To determine the ability to refill and also the patency of the cannula, at intervals of 4 to 6 weeks after implantation, we accessed the drug reservoir with a transconjunctival needle and delivered approximately as low as 1 microL of trypan blue solution (0.06%) into the anterior chamber. Animals were followed up by slit-lamp examination, photography, and fluorescein angiography. RESULTS: Benchtop testing showed 2.0 microL/min delivery when using 0.4 mW of power for electrolysis. One-way valves showed reliable opening pressures of 470 mm Hg. All implanted devices refilled at 4- to 6-week intervals for 4 to 6 months. No infection was seen. No devices extruded. No filtering bleb formed over the implant. CONCLUSIONS: A prototype ocular mini drug pump was built, implanted, and refilled. Such a platform needs more testing to determine the long-term biocompatibility of an electrically controlled implanted pump. Testing with various pharmacologic agents is needed to determine its ultimate potential for ophthalmic use.
PURPOSE: To evaluate the feasibility of developing a novel mini drug pump for ophthalmic use. METHODS: Using principles of microelectromechanical systems engineering, a mini drug pump was fabricated. The pumping mechanism is based on electrolysis, and the pump includes a drug refill port as well as a check valve to control drug delivery. Drug pumps were tested first on the benchtop and then after implantation in rabbits. For the latter, we implanted 4 elliptical (9.9 x 7.7 x 1.8 mm) non-electrically active pumps into 4 rabbits. The procedure is similar to implantation of a glaucoma seton. To determine the ability to refill and also the patency of the cannula, at intervals of 4 to 6 weeks after implantation, we accessed the drug reservoir with a transconjunctival needle and delivered approximately as low as 1 microL of trypan blue solution (0.06%) into the anterior chamber. Animals were followed up by slit-lamp examination, photography, and fluorescein angiography. RESULTS: Benchtop testing showed 2.0 microL/min delivery when using 0.4 mW of power for electrolysis. One-way valves showed reliable opening pressures of 470 mm Hg. All implanted devices refilled at 4- to 6-week intervals for 4 to 6 months. No infection was seen. No devices extruded. No filtering bleb formed over the implant. CONCLUSIONS: A prototype ocular mini drug pump was built, implanted, and refilled. Such a platform needs more testing to determine the long-term biocompatibility of an electrically controlled implanted pump. Testing with various pharmacologic agents is needed to determine its ultimate potential for ophthalmic use.
Authors: Ziad F Bashshur; Ali Bazarbachi; Alexandre Schakal; Zeina A Haddad; Christelle P El Haibi; Baha' N Noureddin Journal: Am J Ophthalmol Date: 2006-07 Impact factor: 5.258
Authors: Robert L Avery; Joel Pearlman; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust; Robert Wendel; Arun Patel Journal: Ophthalmology Date: 2006-10 Impact factor: 12.079
Authors: Mark Humayun; Arturo Santos; Juan Carlos Altamirano; Ramiro Ribeiro; Roberto Gonzalez; Alejandro de la Rosa; Jason Shih; Changling Pang; Fukang Jiang; Philip Calvillo; John Huculak; Jenna Zimmerman; Sean Caffey Journal: Transl Vis Sci Technol Date: 2014-12-01 Impact factor: 3.283
Authors: Aniruddha Agarwal; William R Rhoades; Mostafa Hanout; Mohamed Kamel Soliman; Salman Sarwar; Mohammad Ali Sadiq; Yasir Jamal Sepah; Diana V Do; Quan Dong Nguyen Journal: Clin Ophthalmol Date: 2015-06-05
Authors: Nathan Gooch; Sarah A Molokhia; Russell Condie; Randon Michael Burr; Bonnie Archer; Balamurali K Ambati; Barbara Wirostko Journal: Pharmaceutics Date: 2012-03-08 Impact factor: 6.321
Authors: Sarah J Cohen; Robison V Paul Chan; Mark Keegan; Christopher M Andreoli; Jeffrey T Borenstein; Joan W Miller; Evangelos S Gragoudas Journal: Pharmaceutics Date: 2012-03-12 Impact factor: 6.321